Tylenol Maker Kenvue Rebounds In Premarket After Trump Links Drug To Autism
NeutralFinancial Markets

Kenvue, the maker of Tylenol, has seen a rebound in premarket trading following comments made by former President Trump linking the drug to autism. While this has raised concerns about potential impacts on Tylenol consumption, economists believe the risk to Kenvue's stock is limited. This situation highlights the ongoing debates around pharmaceuticals and public perception, especially when high-profile figures make controversial statements.
— Curated by the World Pulse Now AI Editorial System